Influence of anti-ASGM-1 treatment on the expression of ASGM-1 in restimulated spleen cultures
| Host . | In vivo treatment . | % Antigen-positive cells . | ||
|---|---|---|---|---|
| CD8+ . | CD8+ASGM-1+ . | CD11b+ ASGM-1+ . | ||
| Naive | — | 10.7 | 66 | 94 |
| Naive | α-ASGM-1 | 9.6 | 63 | 90 |
| Sp3/d8 | — | 20.6 | 73 | 89 |
| Sp3/d8 | α-ASGM-1 | 13.2 | 71 | 83 |
| Host . | In vivo treatment . | % Antigen-positive cells . | ||
|---|---|---|---|---|
| CD8+ . | CD8+ASGM-1+ . | CD11b+ ASGM-1+ . | ||
| Naive | — | 10.7 | 66 | 94 |
| Naive | α-ASGM-1 | 9.6 | 63 | 90 |
| Sp3/d8 | — | 20.6 | 73 | 89 |
| Sp3/d8 | α-ASGM-1 | 13.2 | 71 | 83 |
Splenocytes were restimulated in vitro for 5 days, and viable nonadherent cells were directly labeled with α-CD8–PE and α-ASGM-1/FITC-conjugated α-rabbit IgG. After Fc receptor blocking, viable adherent cells were directly labeled with α-CD11b–PE and α-ASGM-1/FITC-conjugated α-rabbit IgG. Results are represented as the percentage of CD8+ cells of total splenocytes, percentage of α-ASGM-1+ cells within the CD8+population, and percentage of α-ASGM-1+ cells within the CD11b+ population.